OTCMKTS:ISCO - International Stem Cell Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.50 +0.02 (+1.35 %) (As of 03/22/2019 04:00 PM ET)Previous Close$1.48Today's Range$1.50 - $1.5052-Week Range$1.25 - $1.90Volume3,769 shsAverage Volume5,490 shsMarket Capitalization$11.30 millionP/E Ratio-1.03Dividend YieldN/ABeta-0.08 ProfileDiscussionChartEarningsFinancialsInsider TradesHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company's human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California. Receive ISCO News and Ratings via Email Sign-up to receive the latest news and ratings for ISCO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ISCO Previous Symbol CUSIP460378102 CIK1355790 Webwww.internationalstemcell.com Phone760-940-6383Debt Debt-to-Equity RatioN/A Current Ratio0.79 Quick Ratio0.54Price-To-Earnings Trailing P/E Ratio-1.03 Forward P/E Ratio-4.69 P/E GrowthN/A Sales & Book Value Annual Sales$7.46 million Price / Sales1.51 Cash FlowN/A Price / Cash FlowN/A Book Value$0.34 per share Price / Book4.41Profitability EPS (Most Recent Fiscal Year)($1.46) Net Income$-6,060,000.00 Net Margins-23.26% Return on Equity-123.16% Return on Assets-31.68%Miscellaneous EmployeesN/A Outstanding Shares7,533,000Market Cap$11.30 million Next Earnings Date4/9/2019 (Estimated) OptionableNot Optionable International Stem Cell (OTCMKTS:ISCO) Frequently Asked Questions What is International Stem Cell's stock symbol? International Stem Cell trades on the OTCMKTS under the ticker symbol "ISCO." How were International Stem Cell's earnings last quarter? International Stem Cell Corp (OTCMKTS:ISCO) announced its earnings results on Thursday, November, 15th. The biotechnology company reported ($0.10) EPS for the quarter. The biotechnology company earned $3.20 million during the quarter. International Stem Cell had a negative net margin of 23.26% and a negative return on equity of 123.16%. View International Stem Cell's Earnings History. When is International Stem Cell's next earnings date? International Stem Cell is scheduled to release their next quarterly earnings announcement on Tuesday, April 9th 2019. View Earnings Estimates for International Stem Cell. Has International Stem Cell been receiving favorable news coverage? News stories about ISCO stock have been trending positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. International Stem Cell earned a coverage optimism score of 2.2 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. Who are some of International Stem Cell's key competitors? Some companies that are related to International Stem Cell include Leap Therapeutics (LPTX), Aerpio Pharmaceuticals (ARPO), Novus Therapeutics (NVUS), Helix Biopharma (HBPCF), DiaMedica Therapeutics (DMAC), Celsion (CLSN), ProPhase Labs (PRPH), AzurRx BioPharma (AZRX), Moleculin Biotech (MBRX), MOTIF BIO PLC/S (MTFB), ContraFect (CFRX), Aptevo Therapeutics (APVO), Novan (NOVN), Oncomed Pharmaceuticals (OMED) and Achaogen (AKAO). What other stocks do shareholders of International Stem Cell own? Based on aggregate information from My MarketBeat watchlists, some companies that other International Stem Cell investors own include Neuralstem (CUR), Turkcell Iletisim Hizmetleri A.S. (TKC), Athersys (ATHX), Adesto Technologies (IOTS), Canopy Growth (CGC), ContraFect (CFRX), Myriad Genetics (MYGN), Array Biopharma (ARRY), CEL-SCI (CVM) and NeXt Innovation (GSVC). Who are International Stem Cell's key executives? International Stem Cell's management team includes the folowing people: Prof. Andrey Semechkin, Co-Chairman & CEO (Age 59)Dr. Russell Kern, Exec. VP, Chief Scientific Officer & Director (Age 33)Ms. Sophia Garnette J.D., VP of Legal Affairs & Operations and Sec. (Age 35)Mr. Francisco Bustamante, Pres of Lifeline Cell Technology LLC How do I buy shares of International Stem Cell? Shares of ISCO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is International Stem Cell's stock price today? One share of ISCO stock can currently be purchased for approximately $1.50. How big of a company is International Stem Cell? International Stem Cell has a market capitalization of $11.30 million and generates $7.46 million in revenue each year. The biotechnology company earns $-6,060,000.00 in net income (profit) each year or ($1.46) on an earnings per share basis. What is International Stem Cell's official website? The official website for International Stem Cell is http://www.internationalstemcell.com. How can I contact International Stem Cell? International Stem Cell's mailing address is 5950 PRIESTLY DRIVE, CARLSBAD CA, 92008. The biotechnology company can be reached via phone at 760-940-6383 or via email at [email protected] MarketBeat Community Rating for International Stem Cell (OTCMKTS ISCO)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 84 (Vote Outperform)Underperform Votes: 87 (Vote Underperform)Total Votes: 171MarketBeat's community ratings are surveys of what our community members think about International Stem Cell and other stocks. Vote "Outperform" if you believe ISCO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ISCO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/22/2019 by MarketBeat.com StaffFeatured Article: Why do companies engage in swaps?